Incyte and MorphoSys Report First Patient Dosing in P-III inMIND Study for Relapsed or Refractory Follicular or Marginal Zone Lymphoma

 Incyte and MorphoSys Report First Patient Dosing in P-III inMIND Study for Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Incyte and MorphoSys Report First Patient Dosing in P-III inMIND Study for Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Shots:

  • The first patient has been dosed in the P-IIII inMIND study assessing the efficacy and safety of tafasitamab vs PBO in combination with lenalidomide and rituximab in patients with r/r FL and MZL
  • The study is expected to enroll ~600 adults aged≥18yrs. with r/r FL or MZL. The 1EPs is PFS in the FL population and 2EPs are PFS and OS in the overall population as well as PET-CR at the EOT in the FL population
  • Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAb and has received the US FDA’s ODD for FL

Click here to­ read full press release/ article | Ref: Business Wire | Image: Morphosys

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post